1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/06/2024 | RMD | Buy Now | ResMed | $190.40 | 19.22% | Keybanc | Brett Fishbin | → $227 | Initiates | → Overweight | Get Alert |
01/30/2024 | RMD | Buy Now | ResMed | $190.40 | 7.67% | Oppenheimer | Suraj Kalia | $185 → $205 | Maintains | Outperform | Get Alert |
01/30/2024 | RMD | Buy Now | ResMed | $190.40 | 12.92% | Mizuho | Anthony Petrone | $195 → $215 | Maintains | Buy | Get Alert |
01/26/2024 | RMD | Buy Now | ResMed | $190.40 | 2.42% | Mizuho | Anthony Petrone | $180 → $195 | Maintains | Buy | Get Alert |
01/25/2024 | RMD | Buy Now | ResMed | $190.40 | -5.46% | UBS | Saul Hadassin | $175 → $180 | Maintains | Neutral | Get Alert |
01/25/2024 | RMD | Buy Now | ResMed | $190.40 | -4.41% | RBC Capital | Craig Wong-Pan | $181 → $182 | Maintains | Sector Perform | Get Alert |
01/25/2024 | RMD | Buy Now | ResMed | $190.40 | 12.92% | Needham | Mike Matson | $180 → $215 | Maintains | Buy | Get Alert |
01/09/2024 | RMD | Buy Now | ResMed | $190.40 | 2.42% | JP Morgan | David Low | $160 → $195 | Maintains | Overweight | Get Alert |
10/31/2023 | RMD | Buy Now | ResMed | $190.40 | -15.97% | Mizuho | Anthony Petrone | $180 → $160 | Maintains | Buy | Get Alert |
10/27/2023 | RMD | Buy Now | ResMed | $190.40 | -11.24% | Morgan Stanley | Sean Laaman | → $169 | Upgrade | Equal-Weight → Overweight | Get Alert |
10/16/2023 | RMD | Buy Now | ResMed | $190.40 | -8.09% | Oppenheimer | Suraj Kalia | $275 → $175 | Maintains | Outperform | Get Alert |
10/12/2023 | RMD | Buy Now | ResMed | $190.40 | 6.09% | RBC Capital | Craig Wong-Pan | $273 → $202 | Downgrade | Outperform → Sector Perform | Get Alert |
09/29/2023 | RMD | Buy Now | ResMed | $190.40 | — | Wolfe Research | Mike Polark | — | Downgrade | Outperform → Peer Perform | Get Alert |
09/18/2023 | RMD | Buy Now | ResMed | $190.40 | 20.8% | B of A Securities | Lyanne Harrison | $250 → $230 | Maintains | Buy | Get Alert |
09/13/2023 | RMD | Buy Now | ResMed | $190.40 | -5.46% | Mizuho | Anthony Petrone | $255 → $180 | Maintains | Buy | Get Alert |
09/06/2023 | RMD | Buy Now | ResMed | $190.40 | -5.46% | Needham | Mike Matson | → $180 | Upgrade | Hold → Buy | Get Alert |
09/05/2023 | RMD | Buy Now | ResMed | $190.40 | -10.71% | UBS | Saul Hadassin | $265 → $170 | Downgrade | Buy → Neutral | Get Alert |
08/14/2023 | RMD | Buy Now | ResMed | $190.40 | 43.38% | RBC Capital | Craig Wong-Pan | $284 → $273 | Maintains | Outperform | Get Alert |
08/04/2023 | RMD | Buy Now | ResMed | $190.40 | 49.16% | RBC Capital | Craig Wong-Pan | → $284 | Reiterates | Outperform → Outperform | Get Alert |
The latest price target for ResMed (NYSE: RMD) was reported by Keybanc on February 6, 2024. The analyst firm set a price target for $227.00 expecting RMD to rise to within 12 months (a possible 19.22% upside). 25 analyst firms have reported ratings in the last year.
The latest analyst rating for ResMed (NYSE: RMD) was provided by Keybanc, and ResMed initiated their overweight rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ResMed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ResMed was filed on February 6, 2024 so you should expect the next rating to be made available sometime around February 6, 2025.
While ratings are subjective and will change, the latest ResMed (RMD) rating was a initiated with a price target of $0.00 to $227.00. The current price ResMed (RMD) is trading at is $190.40, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.